{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:44:04Z","timestamp":1783723444798,"version":"3.55.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0001017","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T20:38:44Z","timestamp":1302035924000},"page":"e1017","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads"],"prefix":"10.1371","volume":"5","author":[{"given":"Richard O.","family":"Oduor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayode K.","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Bertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Pryde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley C.","family":"Van Voorhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tod P.","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1472-8206.2003.00167.x","article-title":"Treatment perspectives for human African trypanosomiasis.","volume":"17","author":"B Bouteille","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1371\/journal.pmed.0050055","article-title":"Eliminating human African trypanosomiasis: where do we stand and what comes next?","volume":"5","author":"PP Simarro","year":"2008","journal-title":"PLoS Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/1381612023396159","article-title":"Chemotherapy of human African trypanosomiasis.","volume":"8","author":"J Burchmore R","year":"2002","journal-title":"Curr Pharm Des"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(08)60410-8","article-title":"The treatment of human African trypanosomiasis.","volume":"33","author":"J Pepin","year":"1994","journal-title":"Adv Parasitol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.21429","article-title":"The continuing problem of human African trypanosomiasis (sleeping sickness).","volume":"64","author":"PG Kennedy","year":"2008","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/brain\/awp074","article-title":"Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis.","volume":"132","author":"J Rodgers","year":"2009","journal-title":"Brain"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbapap.2005.08.018","article-title":"Protein kinases as drug targets in trypanosomes and Leishmania.","volume":"1754","author":"C Naula","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbapap.2003.11.021","article-title":"Protein kinases as targets for anti-parasitic chemotherapy.","volume":"1697","author":"C Doerig","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cbic.200500034","article-title":"Drug discovery process for kinase inhibitors.","volume":"6","author":"H Weinmann","year":"2005","journal-title":"Chembiochem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1087057108326663","article-title":"High-throughput biochemical kinase selectivity assays: panel development and screening applications.","volume":"14","author":"A Card","year":"2009","journal-title":"J Biomol Screen"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome.","volume":"298","author":"G Manning","year":"2002","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1242\/jcs.00384","article-title":"GSK-3: tricks of the trade for a multi-tasking kinase.","volume":"116","author":"BW Doble","year":"2003","journal-title":"J Cell Sci"},{"key":"ref13","first-page":"95","article-title":"The glamour and gloom of glycogen synthase kinase-3 Trends Biochem.","volume":"29","author":"RS Jope","year":"2004","journal-title":"Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0959-437X(98)80068-3","article-title":"\u03b2-catenin: a key mediator of Wnt Signalling.","volume":"8","author":"K Willert","year":"1998","journal-title":"Curr Opin Genet Dev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","article-title":"Glycogen synthase kinase-3\u03b2 regulates cyclic D1 proteolysis and subcelullar localization.","volume":"12","author":"JA Diehl","year":"1998","journal-title":"Genes Dev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1101\/gad.10.12.1443","article-title":"The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3.","volume":"10","author":"C Yost","year":"1996","journal-title":"Genes Dev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1074\/jbc.M002466200","article-title":"Indirubins Inhibit Glycogen Synthase Kinase-3\u03b2 and CDK5\/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer&apos;s Disease.","volume":"276","author":"S Leclerc","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/med.10011","article-title":"Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.","volume":"22","author":"A Martinez","year":"2002","journal-title":"Med Res Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jmb.2003.08.031","article-title":"Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.","volume":"333","author":"JA Bertrand","year":"2003","journal-title":"J Mol Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.","volume":"50","author":"JJ Liao","year":"2007","journal-title":"J Med Chem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1128\/AAC.00364-08","article-title":"Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.","volume":"52","author":"KK Ojo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure.","volume":"359","author":"P Trouiller","year":"2002","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nsmb.1818","article-title":"Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.","volume":"17","author":"KK Ojo","year":"2010","journal-title":"Nature Structural & Molecular Biology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jep.2006.04.003","article-title":"Anti-infective potential of natural products: How to develop a stronger in vitro \u2018proof-of-concept\u2019.","volume":"106","author":"P Cos","year":"2006","journal-title":"Journal of Ethnopharmacology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jep.2010.05.042","article-title":"In vitro antiprotozoal, antimicrobial and antitumor activity <italic>of<\/italic> Pavetta crassipes K. Schum leaf extracts.","volume":"130","author":"ES Bald\u00e9","year":"2010","journal-title":"Journal of Ethnopharmacology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.","volume":"4","author":"J Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"E892","DOI":"10.1152\/ajpendo.00346.2002","article-title":"Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats.","volume":"284","author":"EJ Henriksen","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.105.090266","article-title":"Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob\/ob mice: molecular characterization in liver and muscle.","volume":"316","author":"O Kaidanovich-Beilin","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1371\/journal.pone.0000837","article-title":"GSK-3b Controls Osteogenesis through Regulating Runx2 Activity.","volume":"2","author":"F Kugimiya","year":"2007","journal-title":"PLoS ONE"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35017574","article-title":"Requirement for glycogen synthase kinase-3\u03b2 in cell survival and NF-k\u03b2 activation.","volume":"406","author":"KP Hoeflich","year":"2000","journal-title":"Nature"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0001017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T06:58:49Z","timestamp":1540277929000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0001017"}},"subtitle":[],"editor":[{"given":"Jayne","family":"Raper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0001017","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,5]]}}}